CGON CG Oncology, Inc.
Q3 2025 10-Q
Filed: Nov 14, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR CG Oncology, Inc. (CGON) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 14, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • Newly added risk factor: potential delays in clinical trials triggered by supply chain disruptions in H1 2025
- • Most materially updated risk: increased competition risk due to three new therapies entering market in Q2 2025
Quarterly Financial SummaryXBRL
Revenue
$2M
▲ +3774.4% YoY
Net Income
-$44M
▼ -114.7% YoY▼ -5.8% QoQ
Operating Margin
-3069.0%
▲ +6273336bp YoY
Net Margin
-2629.5%
▲ +4482396bp YoY
ROE
-6.4%
Total Assets
$730M
EPS (Diluted)
$-0.57
▼ -90.0% YoY▼ -3.6% QoQ
Operating Cash Flow
-$39M
▼ -144.3% YoY▼ -39.1% QoQ
Source: XBRL data from CG Oncology, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on CG Oncology, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.